Palisade Bio (PALI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
Annual meeting scheduled for June 10, 2026, to be held virtually for shareholders of record as of April 15, 2026.
Proxy materials, including the notice, proxy statement, and annual report, are available online, with paper copies available upon request.
Voting matters and shareholder proposals
Election of four directors to serve until the 2027 annual meeting or until successors are duly elected.
Ratification of Baker Tilly US, LLP as independent auditor for fiscal year ending December 31, 2026.
Approval to amend the certificate of incorporation to increase authorized common stock from 300,000,000 to 450,000,000, raising total authorized capital stock to 457,000,000.
Approval of the Amended and Restated 2021 Equity Incentive Plan.
Approval of the Amended and Restated 2021 Employee Stock Purchase Plan.
Advisory vote on executive compensation (say-on-pay).
Approval of equity award grants to non-employee directors.
Board of directors and corporate governance
Four nominees for director positions: J.D. Finley, Donald Williams, Emil Chuang, and Robert F. Baltera, Jr.
Latest events from Palisade Bio
- Advanced PALI-2108 to Phase 2, with strong cash reserves and higher R&D-driven net loss in Q2 2026.PALI
Q2 2026 - PALI-2108 shows strong early clinical results as a targeted oral IBD therapy with Phase 2 trials ahead.PALI
Corporate presentation - Advancing a precision oral PDE4 inhibitor for UC, targeting major unmet needs and pharma interest.PALI
Virtual Investor Closing Bell Series - Lead oral PDE4 prodrug for IBD advances to phase II with strong early data and solid funding.PALI
Jefferies Global Healthcare Conference 2026 - PALI-2108 shows strong Phase 1 safety and efficacy, advancing to Phase 2 with solid financial backing.PALI
Corporate presentation - PALI-2108 shows strong safety and efficacy signals in early IBD trials, with Phase 2 planned.PALI
Corporate presentation - Shelf registration enables up to $300M in offerings to advance IBD drug development amid high risk.PALI
Registration filing - Q1 2026 net loss reached $9.6M as PALI-2108 advanced, with $132.7M in cash reserves.PALI
Q1 2026 - Seven key proposals, including board elections and equity plan updates, are up for shareholder vote.PALI
Proxy filing